VitalStone Financial’s Intellia Therapeutics NTLA Stock Holding History

VitalStone Financial’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-5	Closed	–	–	564
2023 Q2	$0	Buy	+5	New	+$203	﹤0.01%	1001

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

VitalStone Financial's NTLA Position: Q3 2023 in Review

VitalStone Financial sold out of Intellia Therapeutics (NTLA) in Q3 2023, closing a stake of 5 shares.

VitalStone Financial first reported a position in NTLA in Q2 2023 and held it in 1 quarter. The position peaked at $0 in Q2 2023. 284 funds tracked by Wall St. Rank hold NTLA as of Q3 2023.

VitalStone Financial reported no remaining Intellia Therapeutics position as of Q3 2023 after selling out during the quarter.
VitalStone Financial sold 5 Intellia Therapeutics shares in Q3 2023.
VitalStone Financial first reported a position in Intellia Therapeutics in Q2 2023 and held it in 1 quarter.
VitalStone Financial's Intellia Therapeutics position peaked at $0 in Q2 2023.
284 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2023.

Based on VitalStone Financial's 13F filing for Q3 2023, filed 15 Nov 2023.